iLite ADCC Target CD20 (-) Assay Ready Cells

$340.00

The Eagle Biosciences iLite® ADCC Target CD20 (-) Assay Ready Cells are designed for the specific detection of drug potency in serum/plasma as well as neutralizing antibodies. They utilize an assay technique called reporter gene assay ( RPG ) to analyze serum/plasma samples. The reporter genes utilized are encoded with a bioluminescent luciferase (Firefly luciferase). Different levels of luminescence detected from each reporter gene cell indicates different levels of expression. The iLite® ADCC Target CD20 (-) Assay Ready Cells are for research use only.

iLite ADCC Target CD20 (-) Assay Ready Cells

For Research Use Only

The Eagle Biosciences iLite® ADCC Target CD20 (-) Assay Ready Cells are:

  • included as part of the iLite® Anti-CD20 ADCC Activity Set (BM4070)
  • can be used as negative controls together with iLite ADCC Effector (V) Assay Ready Cells and iLite ADCC Target CD20 (+) Assay Ready Cells for measuring the ADCC activity of anti-CD20 antibodies.

Content: >250 μL of iLite ® Assay Ready Cells suspended in RPMI 1640 with 20% FBS, mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).

Storage: -80°C, Cells should be used within 30 min of thawing.


Key benefits of iLite® ADCC Activity Assays

  • Unparalleled sensitivity
  • High serum tolerance
  • Normalization read-out included
  • Negative control available for screening of unspecific activity
  • Easy to use – no culturing required on target or effector cells

Product Developed and Manufactured by Svar Life Science

Additional Information

Summary

The iLite® ADCC Target CD20 (-) Assay Ready Cells are based on a human B lymphocyte cell line, Raji (ATCC# CCL-86), and have been genetically engineered and optimized to be depleted of CD20 expression.

Background

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell.

The idea of employing ADCC to destroy dysfunctional cells by treating patients with antibodies has existed since the discovery of the ADCC mechanism. Rituximab, one of the first of such drugs approved, is a chimeric monoclonal antibody targeting CD20, a surface antigen primarily found on B-cells. The drug was approved by the FDA in 1997 for treatment of chemotherapy resistant Non-Hodgkin B-cell lymphomas, and has since also been approved in Europe for different inflammatory indications.

In addition, other anti-CD20 monoclonal antibodies have been developed, such as ocrelizumab, a humanized (90-95%) antibody, and ofatumumab, a fully human monoclonal. In addition, efforts are being made to enhance the ADCC activity of the antibodies by engineering the glycan patterns of the constant region, such as in obinutuzumab.

Frequently Asked Questions


Manual

Product Manual


Publications

References